Topic for pp is Unstable Angina.

Pharmacological Management PowerPoint Presentations

For this assignment, you are to complete a PowerPoint presentation addressing the specific criteria below.

The PowerPoint presentation will be based on Unstable Angina.
Assignments will be posted in announcements during Week 1. If you cannot locate your assignment contact your faculty.

Your presentation must include the following headings. 

Heading – Title Page
Heading – Pathophysiology of Unstable Angina
Heading – Definitions of the Two Drug Classes for Unstable Angina
Heading – Discussion of 4 Medications (2 drugs from each drug class)
Heading – Pharmacokinetics, Pharmacodynamics, Safety/Monitoring, & Pregnancy/Lactation of the 4 Medications Discussed Earlier
Heading – Contraindications of the 4 Medications Discussed Earlier
Heading – Conclusions
Heading – References (remember to use apa style for the references and use citations not later then 5 years ago). 

Please use the same exact template attached to this post. Just put in the info for my topic assigned. 

Pharmacological Management Project

Student Name


Faculty name

Pathophysiology of assigned disease

Assigned Disease: Primary Biliary Cholangitis

Pathophysiology: Primary biliary cholangitis (PBC, formerly known as primary biliary cirrhosis) is an uncommon cholestatic liver disease characterized by immune-mediated destruction of biliary epithelial cells. PBC is female preponderant and typically presents in the fifth or sixth decade of life. The clinical presentation may include generalized pruritus, dryness of eyes and mouth, fatigue, and upper abdominal discomfort; patients may be asymptomatic. Typical laboratory findings are elevations in serum alkaline phosphatase levels, increased serum immunoglobulin M levels, and the presence of antimitochondrial antibodies or specific subtypes of antinuclear antibodies. A diagnosis of PBC is usually made without histologic examination. When used, liver biopsy typically reveals nonsuppurative granulomatous cholangitis with loss of small bile ducts and lymphocytic portal inflammation. Patients who do not achieve an adequate biochemical response to first-line therapy have a greater risk of disease progression to cirrhosis and may ultimately require liver transplantation.

Definition of the two
assigned drug

Classification 1: Bile Acid Analog

Bile acids aid in the digestion and solubilization of lipophilic nutrients and drugs in the small intestine, they signal endocrine molecules that regulate the glucose, lipid, and energy metabolism through complex and intertwined pathways that are largely mediated by activation of nuclear receptor farnesoid X receptor (FXR) and cell surface G protein-coupled receptor 1, TGR5 (also known as GPBAR1).

Classification 2: Immunomodulatory therapy

Immunomodulatory drugs modify the response of the immune system by increasing (immunostimulators) or decreasing (immunosuppressives) the production of serum antibodies. Immunostimulators are prescribed to enhance the immune response against infectious diseases, tumours, primary or secondary immunodeficiency, and alterations in antibody transfer, among others. Immunosuppressive drugs are used to reduce the immune response against transplanted organs and to treat autoimmune diseases.

Discussion of 4 medications –
2 from each drug classification
(you are to choose the drugs –
they must belong to the drug class)

Classification 1: Bile Acid analog

Drug 1: Actigall (ursodiol)

13 – 15 mg/kg/day orally given in 2 – 4 divided doses

Give with food

Drug 2: Obeticholic acid

5 – 10 mg PO qD

Start 5